We read with interest the Article in The Lancet Diabetes and Endocrinology by Dalong Zhu and colleagues, in which dorzagliatin, a dual-acting, allosteric glucokinase activator, showed a beneficial effect on glycaemic control in a phase 2 trial. Although the introduction of a new class of glucose-lowering drugs with a different mode of action is always welcome, particularly in this era of precision medicine, it is important to question the metabolic consequences of the dorzagliatin-induced reduction in plasma glucose
